C1 inhibitor concentrate is regarded as effective and safe in treating acute attacks of hereditary angioedema caused by C1 inhibitor deficiency. This study investigated the course of disease in 3 women treated frequently with C1 inhibitor concentrate.
Three women are described who received C1 inhibitor concentrate for the treatment of acute attacks of hereditary angioedema and experienced an increase in the frequency of attacks during that treatment period. In a control group of 24 patients aged more than 60 years with hereditary angioedema, the natural course of disease was determined.
The 3 women (ages 50, 69, and 72 years) had received C1 inhibitor concentrate for 27, 18, and 22 years, respectively, for acute abdominal and skin attacks. Before this treatment, all attacks were severe. The treatment was always effective: The attacks were mild, and the duration of the attacks was shortened. During the treatment period, the number of attacks increased slowly but continuously, starting at the onset of treatment and paralleling the course of treatment. At the end of the observation period, the number of attacks increased by 4-fold, 12-fold, and 5-fold in the 3 women, respectively. No factors known to increase the frequency of attacks in hereditary angioedema were found in these patients. The control group did not show a similar increase in attacks during a comparable period of time.
A possible explanation for the increase in the frequency of attacks may lie in the large number of injections of C1 inhibitor concentrate.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.N Engl J Med. 1996; 334: 1630-1634
- Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema.Transfusion. 2005; 45: 1774-1784
- Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency.J Allergy Clin Immunol. 2006; 117: 904-908
- Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema.Allergy. 2008; 63: 751-757
- Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions.Exp Rev Clin Immunol. 2008; 4: 13-20
Conflict of Interest: None.
Authorship: All authors had access to the data and played a role in writing this manuscript.
© 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- C1 Inhibitor Therapy and Hereditary AngioedemaThe American Journal of MedicineVol. 123Issue 4
- PreviewWe read with interest the recent report by Bork and Hardt1 and would like to pose our thoughts to the authors. Certainly, a finding of increased attack frequency in hereditary angioedema patients being treated with C1 inhibitor (C1 INH) therapy is interesting and merits further study. However, a 3-subject review that preselects those patients with severe disease requiring C1 INH therapy on demand versus a retrospective historical control group that has never required any prophylactic therapy may not be the most ideal comparison.